Biodexa Pharmaceuticals plc · NASDAQ:BDRX
Biodexa Pharmaceuticals — Investor Presentation (April 2023)
16 slides from Biodexa Pharmaceuticals's investor presentation, April 2023
Slide 1: Investor Presentation
(NASDAQ:BDRX) Investor Presentation April 2023 Confidential
Slide 2: Disclaimer
Disclaimer The following presentation, including a hard copy of these slides/the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation
Slide 3: Biodexa: Corporate overview
Biodexa: Corporate overview Clinical-stage biotechnology company with proprietary micro and nano delivery technology platforms Focused on rare / orphan brain cancers Dual-listed on NASDAQ: BDRX Headquarters, R&D, pilot scale manufacturing in Cardiff, UK Approximately 20 employees CONFIDENTIAL - NOT
Slide 4: Pipeline
Pipeline ID Technology API Therapeutic Area Administration Formulation Pre-clinical Phase I Phase II Partner MTX110 MidaSolve Panobinostat recurrent GBM Direct to tumour via CED MTX110 MidaSolve Panobinostat DIPG Direct to tumour via CED MTX110 MidaSolve Panobinostat Medulloblastoma Direct to tumour
Slide 5: MTX110
MTX110 MidaSolve™ technology Panobinostat infusion with CED Intratumoral treatment of brain cancers Confidential
Slide 6: Why panobinostat?
Why panobinostat? • In a screen of 83 drugs panobinostat (HDAC inhibitor) was among the most effective agents 1 • Convection-enhanced delivery (CED) to directly infuse panobinostat into the pons of a DIPG orthotopic xenograft model showed: • A marked effect on the rate of DIPG xenograft growth1 • Si
Slide 7: MTX110 – Direct delivery of panobinostat
MTX110 – Direct delivery of panobinostat • MTX110 SynchroMed II Pump • Direct delivery treatment of panobinostat • Re-fillable pump implanted in abdomen • Delivers drug intra-tumorally to target location • Bypasses blood brain barrier • Opportunity to deliver maximal therapeutic dose • Minimises pot
Slide 8: MTX110 – Diffuse Intrinsic Pons Glioma (DIPG)
MTX110 – Diffuse Intrinsic Pons Glioma (DIPG) • Significant unmet medical need • About 300 children diagnosed in the US pa1, over 1,100 worldwide2 • Median survival of approximately 10 months • Resection not possible, no effective treatment3 Gd-MRI showing CED targeted delivery • Phase I programme:
Slide 9: MTX110 - Glioblastoma
MTX110 - Glioblastoma 1400 Control TumVolume (mm3) • Problem: 1200 MTX110 1000 • Many drug failures due to poor BBB penetration 800 600 400 • Potential Solution: 200 0 • MTX110 is delivered intra-tumorally at high doses via CED, by- 0 5 10 15 20 25 30 35 40 Days passing BBB Figure 1. Tumour volume d
Slide 10: MTX110 - Glioblastoma
MTX110 - Glioblastoma • Most common and aggressive form of brain cancer in adults. • Survival with standard of care treatment ranges from approximately 13 to 30 months depending on MGMT methylation. • Standard of care: resection, radiation, limited drug options • Near 100% recurrence • More than 13,
Slide 11: Q-Sphera
Q-Sphera Confidential
Slide 12: Technology: unique 3D microsphere printing
Technology: unique 3D microsphere printing 3D Pharmaceutical Printing Process • Industrial printing technology reinvented • Controlled piezoelectric droplet generation of polymer / API / solvent • Instantaneous de-solvation in anti-solvent fluid jet produces monodispersed microspheres • Frequency of
Slide 13: Clinical validation: Q-octreotide Phase I case study
Clinical validation: Q-octreotide Phase I case study Q-octreotide Sandostatin LAR® Q-octreotide resulted in homogeneous, predictable PK in treated healthy volunteers as compared to the approved long-acting formulation CONFIDENTIAL - NOT FOR PUBLIC DISTRIBUTION Confidential
Slide 14: Q-Sphera: Potential in large molecules (mAb exemplar)
Q-Sphera: Potential in large molecules (mAb exemplar) Q-Protein In Vitro Dissolution 12 Cumulative Release (ug/mg) 10 8 6 4 2 0 0 7 14 21 28 35 42 Time (days) Breakthrough data indicate protein loading up to 17% w/w while retaining functional integrity throughout encapsulation and release, as demons
Slide 15: Milestones 2023
Milestones 2023 Strategic Partnerships Q1’ 23 Q2’ 23 Q3’ 23 Q4’ 23 MTX110 rGBM First Patient First MTX110 Visit (FPFV) MTX110 MTX110 MTX110 MTX110 Phase II DIPG Phase I DIPG rGBM Cohort A rGBM Cohort A Phase II DIPG IND FPFV ‘203 study submitted Progression Progression MTX110 Free Survival safety da
Slide 16: Summary
Summary Clinical stage, rare / orphan oncology focused CED system offers potential for other rare / orphan indications Milestones / catalysts in 2023: Clinical data readouts Multiple pre-clinical data expected • Drug delivery platforms: Partner Utilizing Q-Sphera Platform • MTX110 clinically proven
Biodexa Pharmaceuticals — Investor Presentation (April 2023) on 6ix